JNJ
Goldman’s moving the goalposts
Johnson & Johnson got a fresh thumbs-up from Goldman Sachs, which lifted its price target to $275 from $265 and kept the stock at Buy. In plain English: Wall Street’s still seeing more upside, even after J&J has already put a pretty decent run together.
Why the market cares
This isn’t just a random sticker change on a stock chart. Goldman’s call lands right as J&J is trying to sell investors a familiar but powerful combo: steady pharma cash flow, a growing dividend, and enough operational muscle to keep the machine humming.
And the backdrop is doing some heavy lifting too:
- J&J beat Q1 estimates, with EPS of $2.70 versus $2.68 expected
- Revenue came in at $24.06 billion
- FY2026 EPS guidance got raised to 11.45–11.65
- The quarterly dividend was lifted to $1.34
The fine print, because nothing’s ever that simple
There’s a little less confetti once you squint at the details. Profit and free cash flow fell in Q1, Stelara sales keep getting chewed at by biosimilar pressure, and insiders sold about 30,142 shares last quarter. So yes, the story is strong — but it’s not exactly a fairy tale with a marching band.
Big picture: Goldman’s move says J&J still looks like a dependable dividend-and-defensiveness play, even if a few cracks in the armor are showing.